US Cryo-EM Expansion FairJourney Bio has launched state-of-the-art cryo-EM services in San Diego and opened a dedicated facility there in 2026, signaling a strategic push into the US structural biology market and creating opportunities to partner with US pharma and biotech firms needing high-resolution antibody discovery support.

Imaging Investment A $10 million investment in a microscopy facility underscores a commitment to advanced imaging and structural analysis, enabling deeper antibody screening, characterization and faster data-driven decision-making for early-stage programs.

Global Partner Pitch With a track record of 19 antibodies advancing to clinical stages and an adaptable partnership model, FJBio presents itself as a trusted global CRO for pharma and biotech seeking end-to-end discovery and development.

Growth Capacity Mid-market scale with 201-500 employees and revenue in the $10–$25 million range indicates capacity for multi-program collaborations and potential upsell of premium cryo-EM workflows to accelerate lead optimization.

Leadership Outreach Leadership changes with a new CEO in 2025 and active participation in industry events such as the JP Morgan Healthcare Conference 2026 point to strong strategic direction and opportunities for executive-level partnerships or co-development initiatives.